The Federal Trade Commission is preparing to sue the largest three pharmacy-benefit managers over their tactics for negotiating prices for drugs including insulin, after a two-year investigation into whether the companies steer patients away from less-expensive medicines.
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/18/2024 | $60.00 → $66.00 | Equal Weight → Overweight | Wells Fargo | |
| 11/15/2024 | $1000.00 | Outperform | Wolfe Research | |
| 10/17/2024 | $1100.00 | Outperform | Bernstein | |
| 10/10/2024 | $63.00 → $82.00 | Equal Weight → Overweight | Barclays | |
| 10/4/2024 | $59.00 → $85.00 | Hold → Buy | TD Cowen | |
| 9/13/2024 | $1060.00 | Buy | Citigroup | |
| 8/12/2024 | $1025.00 | Hold → Buy | Deutsche Bank | |
| 6/26/2024 | $400.00 | Overweight | Piper Sandler |
CVS Health Board of Directors appoints four new members: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman Appointments follow productive engagement with Glenview Capital Management WOONSOCKET, R.I., Nov. 18, 2024 /PRNewswire/ -- The Board of Directors of CVS Health (NYSE:CVS) today announced the appointment of four new board members: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman, following productive discussions with Glenview Capital Management. "In our discussions with the leadership at Glenview, we agreed that we can deliver greater value from our
Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from the ALS Association through its Lawrence and Isabel Barnett Drug Development Program for the advancement of ASHA-624, a novel brain-penetrant intra-molecular glue inhibitor of SARM1. The grant will support the continued development of ASHA-624 towards first-in-human clinical trials as a potential disease-modifying therapeutic for Amyotrophic Lateral Sclerosis (ALS). ASHA-624 was designed using Asha's proprietary PRISM™ drug design technology, which creates new medicines to restore normal biology and provide functional cu
Prem Shah named Group President, CVS Health; Steve Nelson named President, Aetna WOONSOCKET, R.I., Nov. 6, 2024 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced Prem Shah will be Group President, and will continue to report to David Joyner, President and Chief Executive Officer. In addition, the company announced the appointment of Steve Nelson as President, Aetna, and he will also report to Joyner. Both appointments are effective today. As Group President, Shah will be responsible for the operational performance and integrated value creation across CVS Caremark, CVS Pha
Financial Highlights Third quarter total revenues increased to $95.4 billion, up 6.3% compared to the prior yearThird quarter GAAP diluted EPS of $0.07 and Adjusted EPS of $1.09Third quarter GAAP diluted EPS and Adjusted EPS include charges to record premium deficiency reserves of approximately $1.1 billion ($0.63 per share) in the Health Care Benefits segmentGenerated year-to-date cash flow from operations of $7.2 billionCEO Commentary "Our integrated model accelerates our ability to uniquely do what is most important to today's health care consumers: deliver lower cost of care, a simpler experience and better outcomes. Our third quarter results reflect strong performance in the Health Serv
Total revenues for the third quarter 2024 increased 30% to $63.7 billionShareholders' net income for the third quarter 2024 was $0.7 billion, or $2.63 per shareAdjusted income from operations1 for the third quarter 2024 was $2.1 billion, or $7.51 per shareReaffirms 2024 outlook2 for adjusted income from operations1,2 of at least $28.40 per shareBLOOMFIELD, Conn., Oct. 31, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) today reported strong third quarter 2024 results demonstrating focused execution across Evernorth Health Services and Cigna Healthcare. "Ou
Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio, total revenue increased 42%, and non-incretin revenue increased 17%.Q3 2024 EPS increased to $1.07 on a reported basis and $1.18 on a non-GAAP basis, both inclusive of $3.08 of acquired IPR&D charges. 2024 revenue guidance range updated to $45.4 to $46.0 billion. 2024 reported EPS guidance updated to the range of $12.05 to $12.55, and non-GAAP EPS guidance updated to the range of $13.02 to $13.52, both driven by the acquired IPR&D charges in
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa
For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ
For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat
SC 13G - CVS HEALTH Corp (0000064803) (Subject)
SC 13G - Cigna Group (0001739940) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics' AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of the Robust Predictive Power of CONVERGE® - 83% of Prioritized Targets were Validated in Disease-Relevant Models, a Rate Significantly Higher than Industry Standards SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery and development, announced today that Eli Lilly & Company ("Lilly") (NYSE:LLY) has opted to pursue the development of therapeutics against two validated drug targets for
INDIANAPOLIS, Nov. 19, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1, 2024. In addition, the company announced that Karen Walker will transition her role with Lilly, resigning as a member of Lilly's board of directors effective Dec. 31, 2024. In 2025, Ms. Walker will collaborate with Lilly on certain digital commercial activities. Mr. Moeller is the chairman of the board, president and chief executive officer of Procter & Gamble (P&G). A strong leader who has served as an integral part of P&G's leadership team for more than two decades, Mr. Moeller has held key positions withi
WOONSOCKET, R.I., Nov. 19, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that Dr. Sreekanth Chaguturu will be President, Health Care Delivery, in addition to his current role as Executive Vice President and Chief Medical Officer of CVS Health. Dr. Chaguturu replaces Mike Pykosz, who has decided to leave the company. "Sree and I worked closely together when he started at CVS Health, serving as chief medical officer of CVS Caremark. In that role, and as the leader of Medical Affairs at our company, Sree has served as a trusted advisor to our clients, their members
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
Wells Fargo upgraded CVS Health from Equal Weight to Overweight and set a new price target of $66.00 from $60.00 previously
Wolfe Research initiated coverage of Eli Lilly with a rating of Outperform and set a new price target of $1,000.00
Bernstein initiated coverage of Eli Lilly with a rating of Outperform and set a new price target of $1,100.00
8-K - ELI LILLY & Co (0000059478) (Filer)
8-K - CVS HEALTH Corp (0000064803) (Filer)
13F-HR - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 15 years by 11.36% on an annualized basis producing an average annual return of 23.33%. Currently, Eli Lilly and Co has a market capitalization of $730.31 billion. Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 15 years ago, it would be worth $23,116.69 today based on a price of $811.09 for LLY at the time of writing. Eli Lilly and Co's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automat
Investors have a strong opinion on Tesla Inc. (NASDAQ:TSLA) unlike other companies such as LVMH Moët Hennessy Louis Vuitton SE (OTC:LVMHF) or Eli Lilly and Co (NYSE:LLY), former Tesla Investor Relations head Martin Viecha said on Wednesday and company CEO Elon Musk agrees. What Happened: “One of the great things about speaking with investors about Tesla is that *everyone* has an opinion about this company, often a strong one,” Viecha wrote on X, formerly Twitter. People, however, do not have such strong opinions on Dior’s parent LVMH, or pharmaceutical company Eli Lilly known for its diabetes and clinical depression drugs, he added. Musk agreed to Viecha, with a short, “Yeah.” Y